














RESEARCH ARTICLE

REVEALS—a longitudinal cohort study of multifaceted respiratory assessment in ALS

JAMES ROONEY^{1,2} , DEIRDRE MURRAY^{1,3} , DARA MELDRUM¹ , AMMAR AL-CHALABI^{4,5} , TOMMY BUNTE⁶, THERESA CHIWER^{4,5} , MUTAHHARA CHOUDHURY^{4,5}, ADRIANO CHIO^{7,8} , LAUREN FENTON¹, JENNIFER FORTUNE¹ , LINDSAY MAIDMENT⁹, UMBERTO MANERA^{7,8} , CHRISTOPHER J. MCDERMOTT^{9,10} , MYRTE MEYJES⁶, RACHEL TATTERSALL^{1,3}, MARIA CLAUDIA TORRIERI⁷ , PHILIP VAN DAMME^{11,12} , ELIEN VANDERLINDEN¹¹, CLAIRE WOOD^{4,5}, LEONARD H. VAN DEN BERG⁶  & ORLA HARDIMAN^{1,3} 


¹Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland, ²Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany, ³Beaumont Hospital, Dublin, Ireland, ⁴Department of Basic and Clinical Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK, ⁵Department of Neurology, King's College Hospital, London, UK, ⁶UMC Utrecht, Utrecht, The Netherlands, ⁷ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy, ⁸Neurology 1, Azienda Ospedale Università Città della Salute e della Scienza, Turin, Italy, ⁹Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, ¹⁰Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK, ¹¹Neurology Department, KU Leuven, University Hospitals Leuven, Leuven, Belgium, and ¹²Department of Neuroscience, KU Leuven, Leuven Brain Institute and VIB Center for Brain & Disease Research, Leuven, Belgium

Abstract

Objective: To systematically assess decline in respiratory measures in amyotrophic lateral sclerosis (ALS) and to examine the impact of sex, disease onset type and baseline morbidity on progression. **Methods:** The REVEALS study (Registry of Endpoints and Validated Experiences in ALS) was conducted between April 2018 and February 2021 in six European ALS centers. Slow and forced vital capacity (S/FVC), sniff nasal inspiratory pressure (SNIP), peak cough flow, amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R), and respiratory morbidity were collected. Data were analyzed using a Bayesian multiple outcomes random effects model. **Results:** Two hundred and eighty participants had a median of three assessments (IQR 2.0, 5.0) over a median of 8 months (IQR 2.3, 14.1). There were 974 data collection timepoints. Differences in respiratory measures and rates of decline between disease-onset and sex subgroups were identified. Females had lower scores in all respiratory measures and females with bulbar onset ALS had faster decline compared with other sub-groups. These differences were not detected by the ALSFRS-r respiratory subscale. Dyspnea, orthopnea, and a higher King's stage at baseline were associated with lower respiratory scores throughout follow-up, while having a regular productive cough at baseline was associated with lower peak cough flow scores. **Conclusion:** Respiratory function declines more quickly in females with ALS compared with males when measured by FVC, SVC, SNIP, or PCF, but not the ALSFRS-R respiratory sub-score. Higher baseline King's staging and the presence of clinical respiratory symptoms at baseline were associated with worse respiratory function. The ALSFRS-R respiratory sub-score is poorly correlated with objective respiratory measurements.

Keywords: Respiratory measurement, ALS disease onset, longitudinal decline

Correspondence: Deirdre Murray, Academic Unit of Neurology, Trinity College Dublin, Room 5.43 Trinity Biomedical Science Institute, Dublin 2, Ireland. E-mail: dmurray1@tcd.ie

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/21678421.2024.2359556>.

(Received 4 January 2024; revised 1 April 2024; accepted 20 May 2024)

ISSN 2167-8421 print/ISSN 2167-9223 online © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
DOI: 10.1080/21678421.2024.2359556

Introduction

Amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) results in progressive decline in respiratory muscle strength and ultimately ventilatory failure (1). Symptoms include shortness of breath and difficulty coughing (2). Declining respiratory function is a prognostic indicator in ALS (3) and clinical guidelines advocate frequent assessment (2,4). Pulmonary function tests including forced vital capacity (FVC), slow vital capacity (SVC), sniff nasal inspiratory pressure (SNIP) and peak cough flow assess decline and guide intervention with non-invasive ventilation (NIV) and cough augmentation devices (2,5,6). In clinical trials, the amyotrophic lateral sclerosis functional rating scale-revised (ALSFERS-R), which includes a respiratory subscale, is used as a primary endpoint (7), but the ability of the respiratory sub-scale to adequately assess respiratory function has been questioned (8), and it does not consider ability to clear bronchial secretions.

Disease heterogeneity presents a challenge for clinical care and trials of new treatments (9) as the disease course differs between patients with spinal- and bulbar-onset disease (10), with overall incidence higher in males, and more females presenting with bulbar-onset disease (11,12). Specific genetic phenotypes manifest in different respiratory decline profiles in sex-based subgroups (13,14), but patterns and rates of decline in respiratory measures in disease-onset and sex subgroups require further definition. Differences in presentation of respiratory dysfunction in males and females have not been defined, and insights into patterns of decline across subgroups is important both for clinical prognostication and for stratification of participants in clinical trials.

Forced and slow vital capacity, commonly used in clinical trials, measure the maximum volume of air that can be exhaled from the lungs during a complete expiration from a position of full inspiration. Vital capacity is a global measure of respiratory function, involving multiple muscle groups and passive recoil of a distended chest. These measures are valid and reliable and have stringently applied international standards (15), as well as guidelines specific to ALS (16). Additional tests including SNIP and peak cough flow are used in clinical practice to guide intervention (2,4,5) and have been used in clinical trials (17). SNIP, measures inspiratory muscle strength and is reported in centimeters of water (cmH₂O), peak cough flow measures the maximal flow of air achieved during a cough and is an indication of the ability to effectively clear secretions (18).

The REVEALS study (Registry of Endpoints and Validated Experiences in ALS) was conducted between April 2018 and February 2021 in six European specialist ALS centers (Beaumont

Hospital, Dublin, Ireland; King's College Hospital, London, UK; University Medical Center, Utrecht, The Netherlands; Azienda Ospedale Università Città della Salute e della Scienza, Turin, Italy; Sheffield Teaching Hospitals, Sheffield and University Hospitals Leuven, Belgium). The aim of the study was to systematically assess longitudinal change in key respiratory measures in ALS and to examine the relationships between these measures and respiratory morbidity.

Using multivariate modeling, we have previously shown that each of the measures, FVC, SVC, SNIP, and peak cough flow demonstrated decline over time, with differential decline in bulbar and spinal-onset patients more clearly demonstrated in SNIP and peak cough flow than in FVC and SVC. We found that although FVC and SVC were strongly correlated, SNIP was only moderately correlated with FVC and SVC, reflecting the assessment of a different aspect of respiratory function using this test (19).

Here, we report the decline in these respiratory measures, including the ALSFERS-R respiratory sub-scale, assessed concurrently over time. The impact of possible confounders on the patterns of decline in respiratory measurements, in particular the patterns evident in males and females with spinal- and bulbar-onset ALS is examined. We examine the impact of respiratory symptoms and history at baseline on the measures. We also re-examined the relationships between the respiratory measures.

Methods

Study design

This was a longitudinal, observational study conducted in a real-world clinic setting at six clinical sites (19). Patients attending a participating clinic, with a confirmed diagnosis of spinal or bulbar-onset ALS were eligible to participate. Additional inclusion criteria were: ALS King's stage 2 or 3 at recruitment (20), the ability to provide informed consent, the ability to complete respiratory tests (defined as ability to generate consistent scores, of two valid scores within 10% in SVC and FVC), and the ability to correspond remotely, either independently or with the assistance of a carer. Progression of ALS to the point of using NIV at the time of recruitment or another active respiratory condition (COPD, bronchiectasis, lung cancer, etc.) was exclusion criteria. Reassessment at irregular intervals was acceptable in light of the "real world" design of the study, although 3-monthly assessments in line with guidelines on clinical review were targeted. All assessors completed training in outcome measurement procedures and received regular site visits, including

data collection observation, which ensured consistency of the protocol across the sites.

Outcome measures

Four respiratory outcome measurements were collected in the same order at each visit with the maximum score recorded for analysis; SNIP (cmH₂O) (at least 10 trials), peak cough flow (liters (L)/min) (at least six trials), SVC (L and % predicted), and FVC (L and %predicted) (3–5 trials). The %predicted score of FVC was calculated using global lung function initiative (GLI) reference equations (21) and the %predicted for SVC was calculated using the ratio provided by FVC [$\%pred\ SVC = (FVC\ \%pred \times SVC\ (L)) \div FVC\ (L)$]. The procedures for these assessments have been described in detail previously (19) and adhered to standard operating procedures (16). Potential issues that may affect successful completion of SNIP (nasal surgery or deviation, congestion or other issues) were recorded.

In addition, demographic and clinical variables were collected at baseline including site of ALS onset (spinal/bulbar), date of onset, date of diagnosis, sex, height, weight, King's staging, history of chest infections, smoking history (ever vs. never smoked), and the presence of orthopnea, dyspnea at rest, dyspnea when active or having a regular productive cough (defined as regularly needing to clear phlegm). The ALSFRS-R was completed (16) and the ALSFRS-R respiratory sub-scale was calculated. Chest infection incidence and symptoms were collected at clinic visits and prospectively via fortnightly text message.

Data were collected from April 2018 until February 2020 at which time the Covid-19 pandemic affected in-person respiratory measurement. In-person assessment recommenced in Leuven, and in a limited capacity in Utrecht in July 2020, but remained suspended in other sites. Collection of chest infection incidence continued via fortnightly text messages in most sites and some sites collected ALSFRS-R and other subjective questions by phone. The study concluded as planned in February 2021.

Statistical methods

A descriptive analysis of participants was performed and correlations between outcome measures were calculated for the entire cohort and stratified by site of onset. We refit the previous Bayesian multiple outcomes random effects model (19) to the updated dataset. Random intercepts and random slopes (over time) per individual were included for each outcome (using the Gaussian family for outcome variables), while fixed effects were included for the time from baseline (where the baseline was defined as study enrollment date),

site of onset and sex in interaction with time from baseline, and study site. We updated the model to recode site of onset and sex into a single four level variable (“Male spinal-onset”, “Male bulbar-onset”, “Female spinal-onset”, and “Female bulbar-onset”) to allow for differing rates of decline by sex as well as by site of onset. In addition, the model included terms for correlation both between and within individuals and for residual correlation between outcomes. A total of 3500 model iterations were run and model convergence and fit were assessed by assessing the bulk effective sample size and tail effective sample size, and posterior predictive checks. Models were fit using absolute value for FVC and SVC (i.e. measured in liters) and using percent predicted FVC and SVC, with all other parameters the same as for the best fit model selected in the interim analysis (19). Visit timepoints missing any respiratory outcome measure, or individuals missing any explanatory variables were excluded from the models.

The base model was extended to include the ALSFRS-R respiratory sub-score as an additional Gaussian outcome variable. This model was also fit using absolute value for FVC and SVC (i.e. measured in liters) and using percent predicted FVC and SVC.

The model was further extended to include additional clinical variables of particular interest as fixed effects. To avoid reverse causality, investigational explanatory variables included baseline variables: staging, history of respiratory tract infections, smoking history, orthopnea, dyspnea at rest, dyspnea when active or having a regular productive cough. These models were fit using the %predicted FVC and SVC scores.

Software: R statistical software 4.3.2 with additional packages was used for data preparation and descriptive analysis (22–26), and R packages brms (27), tidybayes (28), bayesplot (29), and Stan software version 2.29.2 were used to fit and assess Bayesian models. Analysis code is available on Github: https://github.com/jpkrooney/REVEALS_Final_BayesMultivariateAnalysis, and archived on Zenodo: <https://zenodo.org/doi/10.5281/zenodo.10863865>

Results

Table 1 summarizes the baseline characteristics of REVEALS participants. Compared with the interim analysis (19), the median follow-up time increased from 6 to 12 months. In total, there were 974 in-clinic data collection timepoints, of which 138 (14.2%) were missing at least one respiratory assessment (SNIP 9.2%, SVC 12.5%, FVC 11.8%, and PCF 9.4% missing). Exclusion of timepoints with missing outcomes resulted in

Table 1. Baseline characteristics of the REVEALS study stratified by recruitment site.

N	Total cohort 280	Dublin 63	London 22	Leuven 59	Sheffield 22	Turin 56	Utrecht 58	p Value*
Female, n (%)	93 (33.2)	22 (34.9)	9 (40.9)	21 (35.6)	8 (36.4)	17 (30.4)	16 (27.6)	
Male, n (%)	187 (66.8)	41 (65.1)	13 (59.1)	38 (64.4)	14 (63.6)	39 (69.6)	42 (72.4)	0.845
Spinal-onset, n (%)	227 (81.1)	53 (84.1)	16 (72.7)	49 (83.1)	21 (95.5)	43 (76.8)	45 (77.6)	
Bulbar-onset, n (%)	53 (18.9)	10 (15.9)	6 (27.3)	10 (16.9)	1 (4.5)	13 (23.2)	13 (22.4)	0.316
King's 2, n (%)	167 (59.6)	50 (79.4)	15 (68.2)	24 (40.7)	13 (59.1)	37 (66.1)	28 (48.3)	
King's 3, n (%)	113 (40.4)	13 (20.6)	7 (31.8)	35 (59.3)	9 (40.9)	19 (33.9)	30 (51.7)	
Height in cm (mean (SD))	172.10 (10.05)	170.55 (8.99)	170.56 (8.58)	170.19 (9.71)	172.82 (12.58)	169.71 (8.57)	178.24 (10.07)	<0.001
N missing height	3	3	0	0	0	0	0	
Weight in kg (mean (SD))	74.67 (14.05)	76.28 (13.20)	75.00 (15.06)	73.72 (14.51)	76.15 (17.49)	67.01 (11.47)	81.00 (11.77)	<0.001
N missing weight	14	11	0	0	3	0	0	
Age at diagnosis (mean (SD))	61.85 (11.85)	63.26 (12.10)	60.43 (13.28)	61.61 (11.99)	56.49 (12.69)	64.37 (10.85)	60.70 (11.05)	0.115
Median diagnostic delay (SD)	9.99 [6.67, 16.33]	9.28 [5.89, 16.13]	ND	9.26 [6.46, 12.80]	ND	11.99 [6.97, 18.25]	10.87 [6.80, 16.33]	0.404
Months from onset to study baseline, median (SD)	19.42 [11.65, 35.12]	17.71 [9.58, 28.48]	ND	26.28 [12.07, 55.72]	ND	21.49 [14.92, 35.43]	17.26 [11.40, 26.60]	0.056
Median in-clinic follow-up time [IQR]	8.0 [2.3, 14.1]	5.8 [2.1, 11.6]	0.00 [0.0, 0.6]	11.9 [5.3, 23.9]	4.1 [0.0, 7.4]	8.9 [2.7, 13.4]	12.3 [3.4, 5.9]	<0.001
Median remote follow-up time [IQR]	12.0 [4.9, 18.1]	15.9 [10.5, 25.0]	4.7 [3.8, 10.5]	15.6 [8.6, 26.6]	9.1 [2.7, 11.9]	9.7 [4.5, 15.7]	13.9 [5.3, 16.5]	<0.001
Median number of assessments per individual [IQR]	3.00 [2.0, 5.0]	3.00 [2.0, 4.0]	1.00 [1.0, 2.0]	4.00 [3.0, 7.0]	2.00 [1.0, 2.75]	4.00 [2.0, 4.0]	4.00 [2.0, 6.0]	<0.001
Mean (SD) FVC in %pred at baseline	79.54 (20.00)	79.21 (22.68)	81.54 (20.45)	77.71 (20.05)	79.53 (13.61)	78.94 (18.22)	81.61 (20.65)	0.929
Mean (SD) SVC in %pred at baseline	76.52 (21.58)	76.24 (23.05)	83.29 (23.69)	75.11 (21.45)	70.70 (15.71)	73.01 (20.55)	80.53 (21.16)	0.232
Mean PCF (SD) at baseline	343.54 (128.86)	360.24 (128.98)	331.90 (159.99)	341.36 (143.36)	301.10 (88.74)	326.52 (124.16)	363.62 (115.50)	0.316
Mean SNIP (SD) at baseline	61.55 (27.91)	61.55 (27.91)	58.57 (24.32)	55.22 (26.99)	58.65 (27.93)	64.12 (31.77)	64.12 (31.77)	0.334
Median [IQR] ALSFRS-R respiratory at baseline	12.00 [11.00, 12.00]	12.00 [11.00, 12.00]	12.00 [11.00, 12.00]	12.00 [10.00, 12.00]	12.00 [11.00, 12.00]	12.00 [11.00, 12.00]	12.00 [11.00, 12.00]	0.325

N: number of participants; %: percentage of cohort; SD: standard deviation; IQR: interquartile range; ND: no data, date of onset not available.

*p Value of categorical variables calculated using Fisher's exact test, Student's *t*-test for normally distributed continuous variables, and the Kruskal–Wallis Rank Sum Test for non-normal continuous variables.

11(4%) of participants being excluded from models.

Raw forced vital capacity and SVC measurements were highly correlated (0.95), while peak cough flow had a moderate correlation with FVC (0.77) and SVC (0.77). SNIP was moderately correlated with FVC (0.55), SVC (0.56), and PCF (0.60) (Supplementary Table S1). The ALSFRS-R respiratory sub-score was poorly correlated with all respiratory measurements with correlations ranging from 0.30 to 0.36. The correlation between PCF and SNIP was higher in the bulbar sub-group (0.76). Correlations between the ALSFRS-R respiratory sub-score and respiratory measures were slightly higher in spinal patients (0.33–0.40) and lower in bulbar patients (0.17–0.22). These

correlations were consistent with modeled correlations at six-monthly follow-up timepoints (Supplementary Table S2).

Figure 1 displays the decline in the respiratory measures stratified by sex and site of onset. In general, females have lower values in all measures and over time. The decline in females with bulbar onset disease is particularly steep, compared with males and with females with spinal onset disease. In males, FVC and SVC decline similarly in those with spinal- and bulbar-onset disease, while there is a large difference between the sub-groups in SNIP and PCF scores. Table 2 shows the modeled intercepts and slopes for the four respiratory outcome measures estimated by this model (Supplementary Table S3 and Figure S1 show the

corresponding results using values in liters for FVC and SVC). Estimates for SNIP and PCF are minimally different, indicating that the transformation of FVC and SVC from liters to percent predicted has a minor impact on the overall model fit.

Figure 2 shows the model with the ALSFRS-R respiratory sub-score included as a fifth outcome variable. The ALSFRS-R respiratory sub-score does not distinguish spinal and bulbar-onset disease in females as the four respiratory measurements do (the credible intervals for spinal vs. bulbar-onset fits overlap more completely than for the other outcomes). Table 3 shows the modeled intercepts and slopes for the five outcome measures estimated by the same model used to generate Figure 2. The equivalent for FVC and SVC in liters is shown in supplementary Table S4 and Figure S2. The estimates for SNIP and PCF have only minor differences between Table 3 and Table S4.

Table 4 shows the results of models extended to include investigational explanatory variables. King's stage 3 at baseline was associated with lower respiratory metrics across the course of follow-up when compared to King's stage 2. However, a history of having ever smoked at baseline was not associated with differences in respiratory metrics, nor was having a history of respiratory tract infections at baseline associated with respiratory outcome measures. Orthopnea and dyspnea at rest and when active at baseline were all associated with reduced respiratory scores, with dyspnea at rest having the most negative parameter estimates. Having a regular productive cough at baseline was associated with a reduced PCF score.

Discussion

This multicenter observational study analyzed the decline in commonly used respiratory measures (FVC, SVC, SNIP, PCF, and ALSFRS-R respiratory sub-score) in disease-onset and sex sub-groups and found significant differences between the groups. Females had lower scores in all measures at all timepoints and females with bulbar onset ALS had faster decline compared with all other sub-groups. Clinical symptoms recorded at baseline, including the presence of dyspnea and orthopnea and a higher King's Stage were associated with lower scores on respiratory tests throughout follow-up, while having a regular productive cough at baseline was associated with a lower peak cough flow score.

The study recruited people in the middle stages of ALS (King's stage 2 and 3), who were likely to experience respiratory decline, while being well enough to attend for assessment during follow-up. The percentage of participants with bulbar-onset

disease was less than previously reported in similar European cohorts (30), which is possibly attributed to a relatively long delay from disease-onset to study entry.

Definition of differential trajectories of respiratory measurements when stratified by sex and site of onset in ALS patients is novel. Females had lower scores in all measures at all timepoints, which is particularly apparent using raw SVC and FVC scores, but is also evident using percent predicted scores (accommodating sex, height, and age). Bulbar-onset disease is widely recognized as more common in females and associated with a shorter prognosis (31). Different patterns of decline in males and females with bulbar-onset disease are clearly shown with a steep decline in females with bulbar weakness compared with other sub-groups (Figure 1). Peak cough flow and SNIP measurements show steeper decline in males with bulbar-onset ALS compared with males with spinal-onset, while the pattern of decline in FVC and SVC is similar. The markedly different pattern of decline in males and females with bulbar-onset ALS, particularly in SVC and FVC is likely to reflect differences in the manifestations of the disease on the respiratory system in males and females. Interestingly, the pattern of decline in peak cough flow is similar in males and females overall, while SNIP also declines more steeply in females with bulbar-onset ALS.

A number of clinical prognostic indicators were examined, demonstrating that King's stage 3 at baseline (i.e. the disease was more progressed) was associated with lower respiratory scores throughout follow-up compared with King's stage 2. In addition, we have shown that clinical symptoms at baseline including orthopnea and dyspnea at rest and when active were associated with lower respiratory scores, while having a history of regular productive cough was only associated with a lower peak cough flow score. Causality cannot be determined, but it is likely that weakness of the respiratory musculature and of cough strength results in secretion retention and increased awareness of the patient of the need to clear secretions. This validates the use of screening questions on cough, orthopnea, and dyspnea in clinical practice as indicators of respiratory weakness. However, this association does not translate to a correlation between the objective respiratory measurements and the respiratory sub-scale of the ALSFRS-R, which was weak ($r = 0.3-0.36$), which may be due to the use of arbitrary ranking in the scale. A smoking history at baseline was not associated with respiratory weakness, likely due to the effect of ALS on respiratory function being much larger than any respiratory effect of smoking. Other potential predictive




Figure 1. Conditional effect of site of onset and sex sampled from the multi-outcome Bayesian model using percent predicted FVC and SVC. Number of participants by sex and site of onset: male spinal-onset = 153, female spinal-onset = 64, male bulbar-onset = 27, female bulbar-onset = 24. FVC (%predicted): percent predicted of forced vital capacity as provided by GLI equations; SVC (%predicted): percent predicted of slow vital capacity based upon the GLI ratio for FVC; SNIP (cmH₂O): sniff nasal inspiratory pressure in centimeters of water; PEAK (L/min): peak cough flow (liters per minute).

Table 2. Slopes and intercepts of respiratory measurements after Bayesian modeling of four outcomes using percent of predicted FVC and SVC.

		Intercept		Slope (unit decline per month)	
		Estimate	Credible interval (Q2.5, Q97.5)	Estimate	Credible interval (Q2.5, Q97.5)
<i>Males</i>					
FVC %pred	Spinal	79.3	(73.7, 85.0)	-0.42	(-0.58, -0.27)
	Bulbar	75.1	(61.2, 89.5)	-0.16	(-0.72, 0.39)
SVC % pred	Spinal	76.2	(70.3, 82.2)	-0.30	(-0.46, -0.14)
	Bulbar	72.8	(58.0, 87.8)	-0.32	(-0.92, 0.28)
SNIP (cmH ₂ O)	Spinal	71.5	(63.9, 79.1)	-0.57	(-0.83, -0.31)
	Bulbar	60.1	(41.3, 79.2)	-0.84	(-1.84, 0.15)
PCF (L/min)	Spinal	398.2	(367.3, 429.7)	-2.65	(-3.83, -1.51)
	Bulbar	360.4	(284.5, 437.1)	-5.25	(-9.84, -0.78)
<i>Females</i>					
FVC %pred	Spinal	74.5	(63.1, 86.4)	-0.98	(-1.45, -0.51)
	Bulbar	69.4	(54.8, 84.3)	-2.57	(-3.56, -1.58)
SVC % pred	Spinal	70.8	(58.7, 83.1)	-0.85	(-1.35, -0.34)
	Bulbar	65.2	(49.7, 81.1)	-2.08	(-3.16, -1.01)
SNIP (cmH ₂ O)	Spinal	55.2	(39.8, 70.7)	-0.80	(-1.58, -0.02)
	Bulbar	44.7	(25.1, 64.3)	-2.05	(-3.38, -0.70)
PCF (L/min)	Spinal	266.7	(202.4, 331.9)	-3.56	(-7.02, -0.06)
	Bulbar	239.8	(159.7, 321.4)	-6.27	(-12.42, -0.22)

FVC: forced vital capacity; SVC: slow vital capacity; %pred: percent predicted score provided by the GLI equations; SNIP: sniff nasal inspiratory pressure; cmH₂O: centimeters of water (pressure); PCF: peak cough flow; L/min: liters per minutes; Q: quartile.

features such as ethnicity and BMI were not addressed in this study but warrant investigation in future studies.

The ALSFRS-R respiratory sub-score is poorly correlated with all four objective respiratory measurements particularly in bulbar-onset patients,




Figure 2. Conditional effect of site of onset and sex sampled from the multi-outcome Bayesian model using percent predicted FVC and SVC and extended to include the ALSFRS-R respiratory sub-score as an additional outcome. FVC (%predicted): percent predicted of forced vital capacity as provided by GLI equations; SVC (%predicted): percent predicted of slow vital capacity based upon the GLI ratio for FVC; SNIP (cmH₂O): sniff nasal inspiratory pressure in centimeters of water; PEAK (L/min): peak cough flow (liters per minute).

Table 3. Slopes and intercepts of respiratory measurements, including the ALSFRS-R respiratory sub-scale after Bayesian modeling of the 5 outcomes using percent predicted FVC and SVC.

		Intercept		Slope (unit decline per month)	
		Estimate	Credible interval (Q2.5, Q97.5)	Estimate	Credible interval (Q2.5, Q97.5)
<i>Males</i>					
FVC %pred	Spinal	78.9	(73.3, 84.3)	-0.41	(-0.56, -0.27)
	Bulbar	74.4	(60.0, 88.3)	-0.17	(-0.71, 0.38)
SVC % pred	Spinal	76.0	(69.9, 81.8)	-0.29	(-0.46, -0.14)
	Bulbar	72.2	(56.8, 87.0)	-0.32	(-0.92, 0.27)
SNIP (cmH ₂ O)	Spinal	71.2	(63.6, 78.8)	-0.56	(-0.83, -0.29)
	Bulbar	59.4	(40.5, 78.3)	-0.83	(-1.88, 0.16)
PCF (L/min)	Spinal	396.8	(365.4, 428.0)	-2.60	(-3.82, -1.40)
	Bulbar	358.0	(280.4, 437.3)	-5.30	(-9.98, -0.70)
ALSFRS-R respiratory sub-score	Spinal	11.1	(10.7, 11.6)	-0.10	(-0.15, -0.05)
	Bulbar	11.0	(9.9, 12.0)	-0.04	(-0.24, 0.15)
<i>Females</i>					
FVC %pred	Spinal	74.4	(62.4, 86.1)	-0.99	(-1.45, -0.53)
	Bulbar	68.6	(53.9, 82.7)	-2.59	(-3.63, -1.58)
SVC % pred	Spinal	70.5	(57.8, 82.9)	-0.84	(-1.34, -0.35)
	Bulbar	64.4	(48.8, 79.5)	-2.01	(-3.14, -0.92)
SNIP (cmH ₂ O)	Spinal	55.5	(39.6, 71.3)	-0.80	(-1.60, 0.00)
	Bulbar	43.8	(24.4, 63.0)	-2.04	(-3.48, -0.63)
PCF (L/min)	Spinal	266.8	(201.4, 333.2)	-3.61	(-7.15, -0.11)
	Bulbar	239.1	(157.7, 320.6)	-7.34	(-13.69, -0.93)
ALSFRS-R respiratory sub-score	Spinal	11.0	(10.2, 11.9)	-0.19	(-0.34, -0.04)
	Bulbar	10.7	(9.6, 11.8)	-0.25	(-0.49, -0.02)

FVC: forced vital capacity; SVC: slow vital capacity; %pred: percent predicted score provided by GLI equations; SNIP: sniff nasal inspiratory pressure; cmH₂O: centimeters of water (pressure); PCF: peak cough flow; L/min: liters per minutes; Q: quartile.

Table 4. Regression coefficients for investigational explanatory variables.

Variable/strata (N)	FVC % predicted			SVC % predicted			SNIP (cmH ₂ O)			PCF (L/min)			ALSFRS-R		
	Estimate	Crf: 2.5	Crf: 97.5	Estimate	Crf: 2.5	Crf: 97.5	Estimate	Crf: 2.5	Crf: 97.5	Estimate	Crf: 2.5	Crf: 97.5	Estimate	Crf: 2.5	Crf: 97.5
King's stage 3 (vs. stage 2) at baseline	-9.1	-14.2	-4.12	-9.4	-14.75	-4.11	-8.8	-15.9	-1.9	-44.9	-73.3	-15.9	-0.7	-1.1	-0.3
Ever vs. never smoked at baseline	-1.7	-6.5	3.4	-2.3	-7.5	3.0	3.4	-3.4	10.2	-23.4	-52.8	4.98	0.1	-0.3	0.4
<i>Respiratory history at baseline</i>															
Occasional chest infections	0.9	-5.7	7.6	1.6	-5.4	8.7	3.5	-5.3	12.5	-11.0	-48.8	25.9	0.2	-0.3	0.7
Moderate/frequent chest infections	-1.5	-15.8	13.4	-2.9	-18.8	13.2	-5.0	-25.0	14.9	9.11	-72.2	94.3	-0.2	-1.3	0.9
<i>Respiratory symptoms at baseline</i>															
Orthopnea	-9.3	-17.1	-1.3	-10.3	-18.7	-1.8	-18.6	-29.3	-8.3	-43.9	-87.9	-0.3	-2.2	-2.7	-1.7
Dyspnea at rest	-18.5	-30.4	-6.5	-22.8	-35.8	-10.3	-18.6	-34.7	-2.2	-71.7	-140.5	-4.3	-2.6	-3.4	-1.8
Dyspnea when active	-13.3	-18.9	-7.3	-15.6	-21.7	-9.3	-15.3	-23.1	-7.2	-43.5	-77.0	-9.9	-1.5	-1.9	-1.1
Regular productive cough	-5.1	-10.8	1.0	-4.5	-10.7	2.00	-6.5	-14.4	1.3	-41.7	-74.5	-8.9	-0.5	-0.9	-0.0

which is similar to previous reports (32). The ongoing use of the ALSFRS-R as a global outcome in clinical trials has been regarded as problematic by many authors (8,33,34) and the poor associations further emphasize this issue.

In our interim analysis paper (19), we assessed the correlations between the respiratory measures and reported an almost perfect correlation between FVC and SVC at baseline, which persisted over time, in agreement with previous reports (35). The primary variable of interest in ALS provided by FVC or SVC is the volume of air exhaled, which is likely to be similar regardless of the technique used. SVC is suggested as more appropriate for patients with bulbar-onset ALS, as it does not require a rapid and forceful exhalation, which can be challenging. We collected both SVC and FVC in this study using a facemask from baseline. This was to ensure that issues that were likely to have arisen during the study resulting from an inability to achieve a mouth seal due to evolving bulbar weakness were avoided. This likely contributed to the close correlation between SVC and FVC, but also to the ability of participants to complete the vital capacity tests during follow-up.

The range of estimates for decline in respiratory scores reported in our study is similar to previous reports (Table 5). For PCF, the slope obtained by Rafiq et al. (39) of -5.77 L/min/month falls between our slowest and fastest sub-groups, while that of Tattersall et al. (36) showed a steeper decline at -10.4 L/min/month, which may be explained by the inclusion of participants with more advanced disease. The slope of FVC percent predicted has been reported by Pinto and de Carvalho (35) who found a slope of -2.1% /month. SVC percent predicted on the other hand was reported by three studies (35–37), two of which (35,37) showed faster decline than our fastest sub-group. The slope of SNIP was only reported in two studies (36,38), one of which showed a faster decline than our fastest sub-group (38). Percentage change over two timepoints a mean of 5.2 months apart was reported by another study, which showed a 13.52% decline in SNIP, a 14% decline in ALSFRS-r, and 10.49% decline in FVC (40). The slope of the ALSFRS-R respiratory sub-score was only reported by one of these studies (35) and again was within the range spanned by our slowest and fastest groups.

Limitations of the study include the curtailment of follow-up during the Covid-19 pandemic. Only two sites Leuven and Utrecht were able to collect respiratory measures in-person after February 2020. It is not possible to evaluate the impact of Covid-19 on the respiratory function of participants as Covid-19 infection was not specifically collected. In addition, we were unable to extend the models to allow for non-linear decline,

Table 5. Slopes of respiratory metrics from comparable studies.

	Tattersall et al. (36) <i>n</i> = 106	Andrews et al. (37) <i>n</i> = 893	Pinto and de Carvalho (35) <i>n</i> = 592	Enache et al. (38) <i>n</i> = 256	Rafiq et al. (39) <i>n</i> = 21	Present study ^a (slowest sub- group)	Present study ^a (fastest sub- group)
PCF (L/min)	-10.4	–	–		-5.77	-2.62	-7.32
FVC %pred			-2.1			-0.16	-2.59
SVC %pred	-1.5	-2.7	-2.2			-0.30	-2.03
SNIPcmH ₂ O	-1.6			-3.0		-0.57	-2.05
ALSFRS-R total	-0.81		0.9				
ALSFRS-R respiratory sub-scale			-0.15			-0.05	-0.25

^aData taken from Table 3 indicate that the subgroup comprised of females with bulbar onset disease was the fastest progressing subgroup for all measures. Males with spinal onset disease were the subgroup whose SVC, PCF, and SNIP progressed most slowly, while males with bulbar onset disease had the lowest slope for FVC and ALSFRS-R respiratory subscale.

as this requires a larger dataset. Future studies utilizing larger datasets, which include detailed respiratory and clinical data collected should replicate the analysis and consider non-linear patterns of decline (41). The findings are applicable to the middle stages of ALS (Kings stage 2 and 3) and future studies should examine the findings across all stages of ALS. Future work using the current dataset will include analysis of the frequency and impact of respiratory tract infections and analysis of the association between reported symptoms and morbidity and respiratory test scores.

Conclusion

Using Bayesian methods, we have shown that respiratory function declines more quickly in female ALS patients when compared to males when measured by FVC, SVC, SNIP, or PCF, but not the ALSFRS-R respiratory sub-score. Furthermore, females with bulbar onset ALS decline fastest. In addition, we showed that the presence of baseline clinical symptoms including breathlessness in lying, dyspnea at rest and dyspnea when active and a higher King's staging at baseline were associated with lower respiratory scores over time. Furthermore, we showed that the ALSFRS-R respiratory sub-score is poorly correlated with objective respiratory measurements.

Acknowledgements

We would like to thank the participants and their families for their contribution to the study and thank the personnel at each site who supported the study.

Ethics approval

Dublin: Ethics (Medical Research) Committee Beaumont Hospital, Dublin 9.

Study Reference 15/62

Utrecht: Medisch Ethische Toetsings Commissie. Study Reference: MvdL/rgj/18/038367.

Leuven: Commissie Medische Ethiek Universitaire, Ziekenhuizen KU Leuven. Study Reference: S60995.

Turin: Comitato Etico Interaziendale, A.O.U. Città della Salute e della Scienza di Torino. Study Reference no. 0029137.

Sheffield and London: IRAS 242722, Study reference STH20135.

Declaration of interest

D. Murray and D. Meldrum have served on an advisory board for Cytokinetics. Professor Chio serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, and Cytokinetics. Prof Al-Chalabi AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Clene Therapeutics, Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, Sano, Sanofi, and Wave Pharmaceuticals. PVD holds a senior clinical investigatorship of FWO-Vlaanderen and is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, the ALS Liga België and the KU Leuven funds “Een hart voor ALS”, “Laeversfonds voor ALS Onderzoek”, and the “Valéry Perrier Race against ALS Fund”. Several authors of this publication are members of the European Reference Network for Rare Neuromuscular Diseases (ERN-NMD).OH reports consulting fees for participation in advisory boards for Biogen, Cytokinetics, Roche, and Pfizer; payment or honoraria for educational events from Biogen, participation on a data safety monitoring board or Advisory Board for Accelsior, and a leadership or fiduciary role as Editor in Chief, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal.

Funding

The study was funded by the Irish Motor Neurone Disease Research Foundation and sponsored by Cytokinetics. This study was performed under the Department of Excellence grant of the Italian Ministry of Education, University and Research to the ‘Rita Levi Montalcini’ Department of Neuroscience, University of Torino, Italy. This is in part an EU Joint Programme—Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu (United Kingdom, Medical Research Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)) and through the Motor Neurone Disease Association. This study represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. CJM is supported by the NIHR Sheffield Biomedical Research Centre and the NIHR Clinical Research Facility at Sheffield Teaching Hospitals NHS Foundation Trust. JR was supported by the European Union Marie Skłodowska-Curie Action (No. 846794).

ORCID

James Rooney  <http://orcid.org/0000-0001-6346-0731>

Deirdre Murray  <http://orcid.org/0000-0002-4314-4480>

Dara Meldrum  <http://orcid.org/0000-0002-7732-3591>

Ammar Al-Chalabi  <http://orcid.org/0000-0002-4924-7712>

Theresa Chiwera  <http://orcid.org/0000-0003-2884-4267>

Adriano Chio  <http://orcid.org/0000-0001-9579-5341>

Jennifer Fortune  <http://orcid.org/0000-0001-8971-1236>

Umberto Manera  <http://orcid.org/0000-0002-9995-8133>

Christopher J. McDermott  <http://orcid.org/0000-0002-1269-9053>

Maria Claudia Torrieri  <http://orcid.org/0000-0001-9312-7497>

Philip Van Damme  <http://orcid.org/0000-0002-4010-2357>

Leonard H. van den Berg  <http://orcid.org/0000-0002-6559-3965>

Orla Hardiman  <http://orcid.org/0000-0003-2610-1291>

References

- Masrori P, Damme PV. Amyotrophic lateral sclerosis: a clinical review. *Eur J Neurol.* 2020;27:1918–29.
- Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS Task Force. *Eur J Neurol.* 2012;19:360–75.
- Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. *Lancet Neurol.* 2018; 17:423–33.
- Overview. Motor neurone disease: assessment and management. Guidance. NICE [Internet]; 2016. Available from: <https://www.nice.org.uk/guidance/ng42>. Accessed August 30, 2023.
- Shoesmith C, Abrahao A, Benstead T, Chum M, Dupre N, Izenberg A, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. *CMAJ.* 2020;192:E1453–E68.
- Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* 2009;73:1218–26.
- van Eijk RPA, Kliet T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. *Curr Opin Neurol.* 2020;33:655–61.
- Pinto S, de Carvalho M. The R of ALSFRS-R: does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis? *Amyotroph Lateral Scler Frontotemporal Degener.* 2015;16:120–3.
- Bendotti C, Bonetto V, Pupillo E, Logroscino G, Al-Chalabi A, Lunetta C, et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener.* 2020;21:485–95.
- Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. *Amyotroph Lateral Scler.* 2009;10:310–23.
- Chiò A, Moglia C, Canosa A, Manera U, D’Ovidio F, Vasta R, et al. ALS phenotype is influenced by age, sex, and genetics: a population-based study. *Neurology.* 2020; 94:e802–e10.
- Trojsi F, D’Alvano G, Bonavita S, Tedeschi G. Genetics and sex in the pathogenesis of amyotrophic lateral sclerosis (ALS): is there a link? *Int J Mol Sci.* 2020;21:3647.
- Rooney J, Murray D, Champion A, Moloney H, Tattersall R, Doherty M, et al. The C9orf72 expansion is associated with accelerated respiratory function decline in a large amyotrophic lateral sclerosis cohort. *HRB Open Res.* 2019;2:23.
- Rooney J, Fogh I, Westeneng HJ, Vajda A, McLaughlin R, Heverin M, et al. C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry.* 2017;88:281.
- Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med.* 2019;200:e70–e88.
- ENCALS. Standard operations manual for outcome measures. Version 2.0. Utrecht: ENCALS; 2018.
- Shefner JM, Watson ML, Meng L, Wolff AA, Neals/Cytokinetics Study Team. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener.* 2013;14:574–81.
- Laveneziana P, Albuquerque A, Aliverti A, Babb T, Barreiro E, Dres M, et al. ERS statement on respiratory muscle testing at rest and during exercise. *Eur Respir J.* 2019;53:1801214.

19. Murray D, Rooney J, Al-Chalabi A, Bunte T, Chiwera T, Choudhury M, et al. Correlations between measures of ALS respiratory function: is there an alternative to FVC? *Amyotroph Lateral Scler Frontotemporal Degener.* 2021; 22:495–504.
20. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. *Brain.* 2012;135:847–52.
21. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the Global Lung Function 2012 Equations. *Eur Respir J.* 2012;40:1324–43.
22. Wickham H. tidyverse: easily install and load the “Tidyverse”. R package version 1.2.1 [Internet]; 2017. Available at: <https://CRAN.R-project.org/package=tidyverse>.
23. Yoshida K. tableone: create “Table 1” to describe baseline characteristics. R package version 0.10.0 [Internet]; 2019. Available at: <https://CRAN.R-project.org/package=tableone>.
24. Pedersen TL. patchwork: the composer of ggplots. R package version 0.0.1 [Internet]; 2017. Available at: <https://github.com/thomasp85/patchwork>.
25. Taiyun W, Simko V. R package “corrplot”: visualization of a correlation matrix [Internet]; 2017. Available at: <https://github.com/taiyun/corrplot>.
26. Walker A. openxlsx: read, write and edit XLSX files; 2015.
27. Bürkner PC. brms: an R package for Bayesian multilevel models using Stan. *J Stat Softw.* 2017;80:1–28.
28. Kay M. tidybayes: Tidy data and Geoms for Bayesian models [Internet]; 2020. Available at: <https://zenodo.org/record/1308151>. Accessed September 3, 2020.
29. Gabry J, Mahr T. bayesplot: plotting for Bayesian models [Internet]; 2019. Available at: <https://mc-stan.org/bayesplot>.
30. Critical issues in ALS case-control studies: the case of the Euro-MOTOR study [Internet]; 2023. Available at: <https://www.tandfonline-com.elib.tcd.ie/doi/epdf/10.1080/21678421.2017.1285939?needAccess=true&role=button>. Accessed March 15, 2023.
31. Turner MR, Scaber J, Goodfellow JA, Lord ME, Marsden R, Talbot K. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. *J Neurol Sci.* 2010;294:81–5.
32. Murray D, Rooney J, Champion A, Fenton L, Hammond M, Heverin M, et al. Longitudinal analysis of sniff nasal inspiratory pressure assessed using occluded and un-occluded measurement techniques in amyotrophic lateral sclerosis and primary lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener.* 2019; 20:481–9.
33. Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry.* 2017;88:381–5.
34. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials [Internet]; 2022. Available at: <https://www.tandfonline.com/doi/epdf/10.1080/21678421.2021.1879865?needAccess=true&role=button>. Accessed December 14, 2022.
35. Pinto S, de Carvalho M. Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. *Amyotroph Lateral Scler Frontotemporal Degener.* 2017;18:86–91.
36. Tattersall R, Murray D, Heverin M, Rooney J, Tobin K, Vance R, et al. Respiratory measurements and airway clearance device prescription over one year in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener.* 2020;21:70–7.
37. Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, et al. Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. *JAMA Neurol.* 2018;75:58–64.
38. Enache I, Pisteu C, Fleury M, Schaeffer M, Oswald-Mammosser M, Echaniz-Laguna A, et al. Ability of pulmonary function decline to predict death in amyotrophic lateral sclerosis patients. *Amyotroph Lateral Scler Frontotemporal Degener.* 2017;18:511–8.
39. Rafiq MK, Bradburn M, Proctor AR, Billings CG, Bianchi S, McDermott CJ, et al. A preliminary randomized trial of the mechanical insufflator–exsufflator versus breath-stacking technique in patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener.* 2015;16:448–55.
40. Pinto S, Geraldès R, Vaz N, Pinto A, de Carvalho M. Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: longitudinal study. *Clin Neurophysiol.* 2009;120:2082–5.
41. McFarlane R, Galvin M, Heverin M, Mac Domhnaill É, Murray D, Meldrum D, et al. PRECISION ALS—an integrated pan European patient data platform for ALS. *Amyotroph Lateral Scler Frontotemporal Degener.* 2023; 24:389–93.